Lee Ainslie's TEVA Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 4.3M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $86.87 M, representing 1.16% of the portfolio. First purchased in 2018-Q4, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 4.3M shares. Largest reduction occurred in Q3 2020, reducing 336.5K shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Lee Ainslie
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2018 | +241,220 | New Buy | 241,220 | $15.42 |
| Q1 2019 | -146,690 | Reduce 60.81% | 94,530 | $15.68 |
| Q2 2019 | -94,530 | Sold Out | 94,530 | $0.00 |
| Q3 2019 | +661,215 | New Buy | 661,215 | $6.88 |
| Q4 2019 | -199,500 | Reduce 30.17% | 461,715 | $9.80 |
| Q1 2020 | -461,715 | Sold Out | 461,715 | $0.00 |
| Q3 2020 | +125,177 | New Buy | 125,177 | $9.01 |
| Q4 2020 | -80,503 | Reduce 64.31% | 44,674 | $9.65 |
| Q1 2021 | +111,167 | Add 248.84% | 155,841 | $11.54 |
| Q2 2021 | -110,962 | Reduce 71.20% | 44,879 | $9.89 |
| Q3 2021 | -44,879 | Sold Out | 44,879 | $0.00 |
| Q4 2022 | +31,449 | New Buy | 31,449 | $9.12 |
| Q1 2023 | +21,416 | Add 68.10% | 52,865 | $8.85 |
| Q2 2023 | -2,277 | Reduce 4.31% | 50,588 | $7.53 |
| Q3 2023 | -17,483 | Reduce 34.56% | 33,105 | $10.20 |
| Q4 2023 | +29,942 | Add 90.45% | 63,047 | $10.44 |
| Q1 2024 | -5,502 | Reduce 8.73% | 57,545 | $14.11 |
| Q2 2024 | +7,938 | Add 13.79% | 65,483 | $16.25 |
| Q3 2024 | +3,296 | Add 5.03% | 68,779 | $18.02 |
| Q4 2024 | -54,624 | Reduce 79.42% | 14,155 | $22.04 |
| Q1 2025 | +16,137 | Add 114.00% | 30,292 | $15.37 |
| Q2 2025 | +4.35 M | Add 14351.64% | 4.38 M | $16.76 |
| Q3 2025 | -77,170 | Reduce 1.76% | 4.3 M | $20.20 |
Lee Ainslie's Teva Pharmaceutical Industries Limited Investment FAQs
Lee Ainslie first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2018, acquiring 241,220 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Teva Pharmaceutical Industries Limited (TEVA) for 28 quarters since Q4 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q2 2025, adding 4,377,690 shares worth $73.37 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Lee Ainslie's firm, Maverick Capital LTD, owns 4,300,520 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $86.87 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 1.16% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 4,377,690 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.